Immix Biopharma, Inc. (IMMX) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US45258H1068
Immix Biopharma, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -29.96 m USD |
| EBIT | -29.96 m USD |
| Net income | -29.44 m USD |
| Diluted EPS – continuing operations | -0.89 USD |
Full history since 2019, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Immix Biopharma, Inc.
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
More stocks
- Novetum (5NB.DU)
- CADIZ INC (CDZI)
- SCG Decor PCL (SCGD.BK)
- DreamTech Co Ltd (192650.KS)
- Chia Ta World Co Ltd (2033.TW)
- Liaoning SG Automotive Group Co Ltd (600303.SS)
- Toyota Caetano (SCT.LS)
- Fulcrum Therapeutics, Inc. (FULC)
- Deutsche Real Estate (DRE2.F)
- Izertis Sa (IZER.MC)
- Anhui Chaoyue Environmental Protection Technology Co. Ltd. (301049.SZ)
- AerSale Corp (ASLE)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.